LLY - Eli Lilly and Company
| Previous Close | 110.23 |
| Open | 110.94 |
| Bid | 110.25 x 1000 |
| Ask | 110.96 x 1000 |
| Day's Range | 109.29 - 111.33 |
| 52 Week Range | 103.66 - 132.13 |
| Volume | 3,317,661 |
| Avg. Volume | 4,059,184 |
| Market Cap | 106.7B |
| Beta (3Y Monthly) | 0.27 |
| PE Ratio (TTM) | 13.95 |
| EPS (TTM) | 7.93 |
| Earnings Date | Oct 23, 2019 |
| Forward Dividend & Yield | 2.58 (2.34%) |
| Ex-Dividend Date | 2019-08-14 |
| 1y Target Est | 123.83 |
- Investor's Business Daily•2 days ago
How AbbVie Plans To Take On Pfizer, Lilly — And Kick Its Humira Habit
Shares of AbbVie leapt higher Friday after the Food and Drug Administration approved its new rheumatoid arthritis treatment — a potential rival to drugs from Eli Lilly and Pfizer.
- Zacks•2 days ago
Pharma Stock Roundup: Pipeline/Regulatory Updates From JNJ, LLY, AZN, RHHBY
FDA approves Roche's (RHHBY) tumor-agnostic medicine, Rozlytrek, J&J's Sirturo for young TB patients.
- Zacks•2 days ago
Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe
The EMA accepts Gilead (GILD) and Galapagos' MAA for filgotinib as a treatment for rheumatoid arthritis.
- Investopedia•3 days ago
The Top Pharma Stocks for 2019
Find out how the pharmaceutical industry is thriving, the new drugs that are coming to market, and the top pharmaceutical stocks for 2019.
- Zacks•3 days ago
Agios Rides High on Tibsovo Sales Amid Acute Competition
Agios' (AGIO) wholly owned precision medicine Tibsovo is picking up sales since its approval and strong sequential growth delivered in Q2. Undue reliance on Celgene for royalties is a constant worry.
- Zacks•4 days ago
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
Style Box ETF report for FTCS
- Zacks•4 days ago
Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study
Lilly's (LLY) Taltz is an important revenue driver for Lilly. Top-line data from a study shows that Taltz helps more plaque psoriasis patients achieve 100% skin clearance compared to Tremfya.
- PR Newswire•4 days ago
Lilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health
INDIANAPOLIS , Aug. 14, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) is launching an open innovation challenge to encourage individuals and teams across the U.S. to identify and submit pioneering ...
- Benzinga•5 days ago
Lilly's Psoriasis Drug Found Superior To J&J's Tremfya In Phase 4 Study
Lilly said Tuesday ahead of the market open that Talz, a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine, met the primary and all major secondary endpoints up to 12 weeks in the Phase 4 IXORA-R study. Taltz has been approved for treating adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, and also for adults with psoriatic arthritis.
- PR Newswire•5 days ago
Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with Moderate to Severe Plaque Psoriasis
INDIANAPOLIS, Aug. 13, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today Taltz® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety of Taltz versus TREMFYA® (guselkumab) in people living with moderate to severe plaque psoriasis (PsO). The IXORA-R trial is the first completed head-to-head (H2H) trial between an IL-17A inhibitor and an IL-23/p19 inhibitor using the Psoriasis Area Severity Index (PASI) 100 score as the primary endpoint.
- Motley Fool•5 days ago
8 Stocks That Have Paid a Dividend for 125 (or More) Consecutive Years
Income stocks don't get more consistent than this.
- American City Business Journals•5 days ago
How one Boston startup rode the diabetes investment wave to raise $126M
When Boston University professor Ed Damiano set out to raise a new tranche of funding for a startup last year, his hopes were low: Diabetes device makers were struggling to raise money in a field that was being increasingly dominated by two players.
- Financial Times•7 days ago
Pharmaceutical groups should invest in public health systems
David Ricks writes that “governments face a clear choice. Mr Ricks, chief executive of Eli Lilly and president of the International Federation of Pharmaceutical Manufacturers & Associations, suggests that drug development should be incentivised in the private sector by extending data exclusivity to further encourage pharmaceutical companies to invest in Alzheimer’s research. In the first instance, it is difficult to see how a public health problem is best tackled by keeping intellectual property in the private sector for even longer than is currently the case.
- Financial Times•7 days ago
US patients struggle to obtain Eli Lilly’s half-price insulin
US diabetes patients are struggling to obtain Eli Lilly’s half-price insulin, which it unveiled shortly before being grilled by Congress about the soaring price of the essential medicine. Only about 3 per cent of insurance claims for Eli Lilly’s insulin were for the cheaper, generic version Insulin Lispro, compared with 97 per cent for its brand name Humalog, according to recent data from GoodRx, an app that tracks drug prices. Many pharmacists do not know that the cheaper version is available — and other patients cannot access it because their insurance or pharmacy benefit manager has not put it on formulary, the list of drugs that are covered.
- Simply Wall St.•8 days ago
Dividend Investors: Don't Be Too Quick To Buy Eli Lilly and Company (NYSE:LLY) For Its Upcoming Dividend
Eli Lilly and Company (NYSE:LLY) is about to trade ex-dividend in the next 3 days. You can purchase shares before the...
Motley Fool•8 days agoDicerna Pharmaceuticals Inc (DRNA) Q2 2019 Earnings Call Transcript
DRNA earnings call for the period ending June 30, 2019.
- PR Newswire•9 days ago
U.S. Court of Appeals Rules in Favor of Lilly in Alimta Alternate Salt Form Patent Lawsuit
INDIANAPOLIS, Aug. 9, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced that the U.S. Court of Appeals for the Federal Circuit ruled in favor of Lilly, confirming that the Alimta® (pemetrexed for injection) vitamin regimen patent would be infringed by competitors that had stated their intent to market alternative salt forms of pemetrexed prior to the patent's expiration in May 2022. The ruling came in the appeals of U.S. District Court decisions in the cases of Eli Lilly and Company v. Dr. Reddy's Laboratories and Eli Lilly and Company v. Hospira, Inc. Previous rulings in Lilly's favor had precluded the generic companies from launching the alternative salt forms until the patent expires.
- Zacks•9 days ago
Nektar (NKTR) Q2 Earnings Beat Estimates, Revenues Miss
Nektar's (NKTR) reports narrower-than expected loss in the second quarter but stock declines.
- Zacks•9 days ago
Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2
Intrexon (XON) posts a narrower-than-expected loss and misses sales estimates in the second quarter of 2019.
- Zacks•9 days ago
Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients
Allergan (AGN) and Novo Nordisk (NVO) report Q2 results. AbbVie's (ABBV) Maviret and Sanofi's (SNY) Dupixent receive approval for new patient population in Europe.
- Zacks•9 days ago
Novo Nordisk (NVO) Q2 Earnings & Revenues Beat Estimates
Novo Nordisk (NVO) beats earnings and sales estimates in the second quarter of 2019.
- Zacks•10 days ago
Top Stock Reports: Disney, Eli Lilly, ADP & More
Top Stock Reports: Disney, Eli Lilly, ADP & More
- Zacks•10 days ago
Celldex (CLDX) Q2 Loss Narrower Than Expected, Revenues Miss
Celldex (CLDX) reports mixed second-quarter results. Revenues fall on reduced collaboration and contract revenues.
- Zacks•10 days ago
Radius (RDUS) Q2 Earnings Beat Estimates, Tymlos Sales Solid
Radius (RDUS) reports a narrower-then-expected loss and beats sales estimates in the second quarter of 2019.
- CNW Group•10 days ago
Lilly Announces Positive Results for Emgality™ (galcanezumab) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments
Lilly Announces Positive Results for Emgality™ (galcanezumab) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments
